Clinical development strategy of immunotherapy combination
Immuno-Oncology Insights 2020; 1(1), 53–68
While cancer immunotherapy has drastically changed cancer treatment, it has now reached a critical point where it is necessary to move the needle again following its initial success in the clinic. Well-organized combinations of immune-oncology (IO) agents with an appropriate subject selection, timing and dose, as well as management of irAE, are necessary bars to reach. To achieve this end, further careful prospective clinical studies based on accumulating knowledge and pre-clinical data are needed.